Common adverse effects of antiretroviral therapy for HIV disease
- PMID: 21671545
Common adverse effects of antiretroviral therapy for HIV disease
Erratum in
- Am Fam Physician. 2011 Jul 15;84(2):154
Abstract
Family physicians are treating patients infected with human immunodeficiency virus in their practices more often. Long-term complications of this disease are multifactorial and can be related to the virus itself or to adverse effects of antiretroviral therapy. Each drug class has side effects: nucleoside/nucleotide reverse transcriptase inhibitors are associated with lactic acidosis, lipodystrophy, and hyperlipidemia; non-nucleoside reverse transcriptase inhibitors are associated with neuropsychiatric symptoms, rash, liver toxicity, and lipid abnormalities; and protease inhibitors are associated with gastrointestinal intolerance and glucose and lipid abnormalities. The entry inhibitor maraviroc and the integrase inhibitor raltegravir have been approved for treatment-naive and treatment-experienced patients. Maraviroc is associated with bronchitis, nasopharyngitis, and esophageal candidiasis. Adverse effects of raltegravir are comparable to those experienced with placebo, with the exception of increased risk of myopathy and rhabdomyolysis. Information about drug interactions for both of these medications is limited. Non-nucleoside reverse transcriptase inhibitors and protease inhibitors are primarily metabolized through the cytochrome P450 system, and as a result have numerous drug-drug interactions. Monitoring for adverse effects of antiretroviral therapy includes a complete blood count and comprehensive metabolic profile every three to six months. A lipid profile and urinalysis for proteinuria should be per- formed annually. Dual energy x-ray absorptiometry should be considered in patients older than 50 years. Long-term morbidity related to antiretroviral therapy includes liver, renal, glucose, and lipid abnormalities, and cardiovascular and bone disease. With some exceptions for lipid management, these morbidities can be managed as in the general population.
Summary for patients in
-
Common side effects of HIV medicines.Am Fam Physician. 2011 Jun 15;83(12):1456-8. Am Fam Physician. 2011. PMID: 21671546 No abstract available.
Similar articles
-
Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.Ann Pharmacother. 2011 Mar;45(3):317-24. doi: 10.1345/aph.1P576. Epub 2011 Mar 8. Ann Pharmacother. 2011. PMID: 21386025
-
[Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].Enferm Infecc Microbiol Clin. 2012 Jun;30(6):e1-89. doi: 10.1016/j.eimc.2012.03.006. Epub 2012 May 23. Enferm Infecc Microbiol Clin. 2012. PMID: 22633764 Spanish.
-
Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.Prescrire Int. 2004 Aug;13(72):144-50. Prescrire Int. 2004. PMID: 15532140
-
[HIV infection, antiretroviral therapy, and endothelium].Herz. 2005 Sep;30(6):472-80. doi: 10.1007/s00059-005-2740-3. Herz. 2005. PMID: 16170677 Review. German.
-
API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.J Assoc Physicians India. 2006 Jan;54:57-74. J Assoc Physicians India. 2006. PMID: 16649742 Review.
Cited by
-
QT prolongation in HIV-positive patients: Review article.Indian Heart J. 2019 Nov-Dec;71(6):434-439. doi: 10.1016/j.ihj.2019.11.259. Epub 2019 Dec 3. Indian Heart J. 2019. PMID: 32248914 Free PMC article. Review.
-
Starting or Switching to an Integrase Inhibitor-Based Regimen Affects PTSD Symptoms in Women with HIV.AIDS Behav. 2021 Jan;25(1):225-236. doi: 10.1007/s10461-020-02967-2. AIDS Behav. 2021. PMID: 32638219 Free PMC article.
-
Traditional Preparations and Methanol Extracts of Medicinal Plants from Papua New Guinea Exhibit Similar Cytochrome P450 Inhibition.Evid Based Complement Alternat Med. 2016;2016:7869710. doi: 10.1155/2016/7869710. Epub 2016 Aug 24. Evid Based Complement Alternat Med. 2016. PMID: 27642356 Free PMC article.
-
Management of Antiretroviral Therapy with Boosted Protease Inhibitors-Darunavir/Ritonavir or Darunavir/Cobicistat.Biomedicines. 2021 Mar 18;9(3):313. doi: 10.3390/biomedicines9030313. Biomedicines. 2021. PMID: 33803812 Free PMC article. Review.
-
Human immunodeficiency virus protease inhibitors modulate Ca2+ homeostasis and potentiate alcoholic stress and injury in mice and primary mouse and human hepatocytes.Hepatology. 2012 Aug;56(2):594-604. doi: 10.1002/hep.25702. Epub 2012 Jun 11. Hepatology. 2012. PMID: 22407670 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical